Zimmer Biomet heads into its August 5 earnings report with the analyst community suddenly more divided — and a fresh upgrade from a major bank reshaping the debate just days before the print.
UBS moved to Buy on July 28, lifting its target from $89 to $115 — a swing of nearly $26 and a complete reversal from a prior Sell rating. That's the sharpest single move in the recent analyst record, and it lands as the stock has recovered to $93.93, up 9% over the past month. The broader analyst backdrop is more cautious: Evercore trimmed its target to $110 from $120 earlier in July while holding Outperform, and BMO initiated at Market Perform with a $95 target — essentially flat to the current price. The consensus is technically Buy, but the cluster of neutral-to-cautious targets in the $90–$95 range suggests the Street is not unanimously convinced by the recovery.
The bull case rests on management's reaffirmed 1–3% organic revenue growth guidance and a raised EPS outlook of $8.40–$8.55 for 2026, supported by healthy elective procedure volumes and a revamped leadership team. Bears push back on a more structural concern: the core large-joints franchise lacks meaningful product innovation, pricing headwinds are real, and meaningful revenue exposure in Europe and Asia adds macro risk. The EPS momentum factor scores rank in the 35th percentile on surprise and the 40th on 90-day momentum — not a strong beat history — though the 12-month forward EPS growth estimate ranks in the 86th percentile, implying analysts expect improvement ahead even if recent delivery has been uneven.
Short interest has eased slightly since the previous preview, falling roughly 2% on the week to just under 5.95% of the free float at approximately 11.8 million shares. That's still up sharply from a month ago — bears rebuilt exposure into the Q2 print and held through it. The July 28 earnings reaction was a 5.5% single-day gain, so some of that short pressure was tested and survived. Borrow conditions remain completely unthreatening: availability is running at 642%, meaning more than six shares are available for every one currently lent out, and cost to borrow is just 0.5%. Options positioning has shifted mildly more constructive relative to recent averages, with the put/call ratio at 0.73 — nearly a full standard deviation below its 20-day mean of 0.84 — suggesting options traders are not hedging aggressively into the release.
The August 5 print will test whether the UBS upgrade thesis — that Zimmer's transformation is further along than the cautious consensus credits — holds up against a revenue and margin profile that has disappointed before.
See the live data behind this article on ORTEX.
Open ZBH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
